InnoPharmax Inc.
4172
Rank in Stocks
#24530
InnoPharmax Inc., established in 1994 and headquartered in Taipei, Taiwan,... InnoPharmax Inc., established in 1994 and headquartered in Taipei, Taiwan, operates as a specialized pharmaceutical enterprise. The company's core activities revolve around the development and market introduction of therapeutic products, with a particular focus on oncology and various other specialized medical fields within the Taiwanese market. Their current commercial portfolio encompasses N11005, an oral insulin designed for administration with meals, alongside GemOral. They also provide an Imipenem and Cilastatin solution, utilized for treating a broad spectrum of bacterial infections affecting areas such as the lower respiratory tract, skin and soft tissue, internal abdominal organs, gynecological systems, and bone and joints. Furthermore, InnoPharmax offers contrast agents, specifically gadopentetate dimeglumine and gadodiamide; oncology medications like Innomustine and Immurin; and Inpheno tablets, which are indicated for rare diseases. The company also provides advanced technology platforms, including the MUCR system, OralPas, and OralPas Pro. Looking at its research and development pipeline, InnoPharmax has several promising candidates. D07001 is currently in Phase I clinical trials for tumor treatment. C08001 has progressed to Phase III, targeting hypertension, heart failure, and left ventricular dysfunction following a myocardial infarction. Additional compounds in pilot bioequivalence (BE) trials include D07002, a potential supplement for phenylketonuria; C07001 for the management of Parkinson's disease; and N11001, which is being investigated for urological applications. The company is also actively formulating new contrast agents, D0131502 and D0051301.
Share Price
$0.27588435
Last synced: 2026-11-10
Market Cap
$32.49M
Change (1 day)
-3.83%
Change (1 year)
-50.57%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade InnoPharmax Inc. (4172)
Category
Healthcare
Operating Margin for InnoPharmax Inc. (4172)
Operating Margin as of November 2026 TTM: -285.80%
According to InnoPharmax Inc.'s latest financial reports, its current operating margin (TTM) is -285.80%. At the end of 2025 the company had an operating margin of -248.98%.
Operating Margin history for InnoPharmax Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -285.80% | 14.79% |
| 2025 | -248.98% | -16.22% |
| 2024 | -297.18% | 111.17% |
| 2023 | -140.73% | -56.07% |
| 2022 | -320.35% | 107.00% |
| 2021 | -154.76% | 598.69% |
| 2020 | -22.15% | -74.91% |
| 2019 | -88.29% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -100.07% |
DE
|
|
| 19.68% | -100.07% |
DE
|
|
| 13.26% | -100.05% |
JP
|
|
| 17.08% | -100.06% |
CH
|
|
| 14.92% | -100.05% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about InnoPharmax Inc.'s operating margin
What is InnoPharmax Inc.'s operating margin?
InnoPharmax Inc.'s operating margin is -285.80%, as of Nov 2026.
What was InnoPharmax Inc.'s operating margin in 2025?
In 2025, InnoPharmax Inc.'s operating margin was -248.98%, compared with -297.18% in 2024.
How has InnoPharmax Inc.'s operating margin changed since 2020?
From 2020 to 2025, InnoPharmax Inc.'s operating margin was highest in 2020 (-22.15%) and lowest in 2022 (-320.35%).
How does InnoPharmax Inc.'s operating margin compare with similar companies?
InnoPharmax Inc.'s operating margin (-285.80%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.